Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT4706 in Advanced Solid Tumors
NCT05148325Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Sep 2021
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAT-4706 in solid tumor (advanced stage) and melanoma, sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Sep 2021; status: completed.
02
Drugs
BAT-4706
03
Conditions
solid tumor (advanced stage)melanoma
Beyond the preview
Go deeper on NCT05148325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148325.